Guardian Pharmacy Services, Inc. (GRDN) P/E Ratio History
Historical price-to-earnings valuation from 2025 to 2026
Loading P/E history...
GRDN Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, Guardian Pharmacy Services, Inc. (GRDN) trades at a price-to-earnings ratio of 46.5x, with a stock price of $36.28 and trailing twelve-month earnings per share of $0.83.
The current P/E is 11% above its 5-year average of 41.8x. Over the past five years, GRDN's P/E has ranged from a low of 39.1x to a high of 45.4x, placing the current valuation at the 100th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, GRDN trades at a 108% premium to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
The PEG ratio of 2.48 (P/E divided by 144% EPS growth) suggests the stock may be expensive relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, GRDN commands a significant premium over the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GRDN DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
GRDN P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $2B | 978.1 | - | -84% | |
| $2B | 128.5 | - | -79% | |
| $111B | 62.8 | - | -62% | |
| $92B | 29.2 | 0.75Best | +15% | |
| $44B | 28.7 | - | +87%Best | |
| $27B | 30.9 | 1.70 | +26% | |
| $10B | 29.8 | 2.16 | +14% | |
| $2B | 13.9Lowest | - | -29% | |
| $2B | 18.7 | 0.93 | +23% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
GRDN Historical P/E Data (2025–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $37.66 | $0.83 | 45.4x | +9% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $30.09 | $0.77 | 39.1x | -7% |
| FY2025 Q3 | $26.23 | $0.64 | 41.0x | -2% |
Average P/E for displayed period: 41.8x
See GRDN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GRDN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GRDN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGRDN — Frequently Asked Questions
Quick answers to the most common questions about buying GRDN stock.
Is GRDN stock overvalued or undervalued?
GRDN trades at 46.5x P/E, near its 5-year average of 41.8x. The 100th percentile ranking places valuation within normal historical bounds.
How does GRDN's valuation compare to peers?
Guardian Pharmacy Services, Inc. P/E of 46.5x compares to sector median of 22.3x. The premium reflects expected growth above peers.
What is GRDN's PEG ratio?
GRDN PEG ratio is 2.48. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2025-2026.